Selective estrogen receptor degrader

Selective estrogen receptor degrader
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

A Selective Estrogen Receptor Degrader (SERD) is a type of drug that targets the estrogen receptor (ER) for degradation. SERDs are used primarily in the treatment of hormone receptor-positive breast cancer.

Mechanism of Action

SERDs function by binding to the estrogen receptor and inducing a conformational change that targets the receptor for degradation by the proteasome. This process effectively reduces the number of estrogen receptors available in the cell, thereby diminishing the cell's response to estrogen. Unlike selective estrogen receptor modulators (SERMs), which can act as either agonists or antagonists depending on the tissue, SERDs consistently act as antagonists by promoting receptor degradation.

Clinical Applications

SERDs are primarily used in the treatment of breast cancer, particularly in cases where the cancer is estrogen receptor-positive. This subtype of breast cancer relies on estrogen signaling for growth and proliferation, making SERDs an effective therapeutic option.

Breast Cancer

In the context of breast cancer, SERDs are often used in patients who have developed resistance to other forms of endocrine therapy, such as aromatase inhibitors or SERMs like tamoxifen. The ability of SERDs to degrade the estrogen receptor makes them a valuable option in overcoming resistance mechanisms that involve receptor mutations or alterations in receptor expression.

Examples of SERDs

One of the most well-known SERDs is fulvestrant, which is approved for the treatment of hormone receptor-positive metastatic breast cancer. Fulvestrant is administered via intramuscular injection and has been shown to be effective in patients who have progressed on other endocrine therapies.

Development of New SERDs

Research is ongoing to develop new SERDs with improved pharmacokinetic properties and efficacy. These efforts include the development of orally bioavailable SERDs, which would offer a more convenient administration route compared to injectable options like fulvestrant.

Side Effects

The side effects of SERDs can include hot flashes, nausea, fatigue, and joint pain. These side effects are generally similar to those observed with other forms of endocrine therapy.

Conclusion

Selective Estrogen Receptor Degraders represent a significant advancement in the treatment of hormone receptor-positive breast cancer. By targeting the estrogen receptor for degradation, SERDs offer a unique mechanism of action that can be effective in cases where other therapies have failed. Ongoing research and development of new SERDs continue to expand the therapeutic options available for patients with breast cancer.

Drug groups | Encyclopedia | Dictionary | Cancer drugs | OTC | Alternative meds | Drugs | Medications A-Z | FDA approved products | Portal:Pharmacology